Overview

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]

Status:
Completed

Trial end date:
2010-11-01

Target enrollment:

Participant gender:

Summary

Investigation into the long-term safety and efficacy of OPC-41061 in repeated oral administrations at doses of 15 mg twice daily in patients with ADPKD who completed the preceding dose-finding study (156-04-001).

Phase:

Phase 2

Details

Lead Sponsor:

Otsuka Pharmaceutical Co., Ltd.

Treatments:

Tolvaptan